Atmosphere-ph.ru

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Лечебное дело
2021 / N 2

Лекарственно-индуцированная диарея
О.Д. Остроумова, М.И. Куликова, Д.А. Сычев

Список литературы

1. Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, Ramakrishna BS, Goh KL, Thomson A, Khan AG, Krabshuis J, LeMair A; WGO. Acute diarrhea in adults and children: a global perspective. Journal of Clinical Gastroenterology 2013 Jan;47(1):12-20.
2. Barr W, Smith A. Acute diarrhea. American Family Physician 2014 Feb;89(3):180-9.
3. DuPont HL. Acute infectious diarrhea in immunocompetent adults. The New England Journal of Medicine 2014 Apr;370(16):1532-40.
4. Philip NA, Ahmed N, Pitchumoni CS. Spectrum of drug-induced chronic diarrhea. Journal of Clinical Gastroenterology 2017 Feb;51(2):111-7.
5. Drug induced diseases: prevention, detection, and management. Tisdale JE, Miller DA, editors. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 p.
6. Shiber S, Yahav D, Avni T, Leibovici L, Paul M. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. The Journal of Antimicrobial Chemotherapy 2015 Jan;70(1):41-7.
7. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52.
8. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. The American Journal of Medicine 1985 Jun;78(6A):73-8.
9. Teppler H. Safety and tolerability of ertapenem. The Journal of Antimicrobial Chemotherapy 2004 Jun;53(Suppl 2):ii75-81.
10. Norrby SR, Gildon КМ. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scandinavian Journal of Infectious Diseases 1999;31(1):3-10.
11. Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ. Ertapenem: review of a new carbapenem. Expert Review of Anti-Infective Therapy 2005 Feb;3(1):23-39.
12. Zhanel GG, Simor AE, Vercaigne L, Mandell L; Canadian Carbapenem Discussion Group. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. The Canadian Journal of Infectious Diseases 1998 Jul;9(4):215-28.
13. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Alimentary Pharmacology & Therapeutics 1998 Dec;12(12):1217-23.
14. Gooch WM 3rd, Philips A, Rhoades R, Rosenberg R, Schaten R, Starobin S. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. The Pediatric Infectious Disease Journal 1997 Feb;16(2 Suppl):S21-4.
15. Harrison CJ, Chartrand SA, Pichichero ME. Microbiologic and clinical aspects of a trial of once daily cefixime compared with twice daily cefaclor for treatment of acute otitis media in infants and children. The Pediatric Infectious Disease Journal 1993 Jan;12(1):62-9.
16. Meyers BR. Comparative toxicities of third-generation cephalosporins. The American Journal of Medicine 1985 Aug;79(2A):96-103.
17. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Safety1993 Aug;9(2):132-42.
18. Nahata MC, Miller MA. Diarrhoea associated with ceftriaxone and its implications in paediatric patients. Journal of Clinical Pharmacy & Therapeutics 1989 Aug;14(4):305-7.
19. Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. The American Journal of Medicine 1988 Sep;85(3A):6-13.
20. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Safety 2000 Jan;22(1):53-72.
21. Swartzberg JE, Maresca RM, Remington JS. Clinical study of gastrointestinal complications associated with clindamycin therapy. The Journal of Infectious Diseases 1977 Mar;135 (Suppl):S99-103.
22. Arguedas A, Emparanza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ, Espinoza G. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. The Pediatric Infectious Disease Journal 2005 Feb;24(2):153-61.
23. Weber FH Jr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. The American Journal of Gastroenterology 1993 Apr;88(4):485-90.
24. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. The Journal of Pediatric Pharmacology and Therapeutics 2015;20(2):90-104.
25. Bucher HC, Tschudi P, Young J, Périat P, Welge-Lüussen A, Züst H, Schindler C; BASINUS (Basel Sinusitis Study) Invetigators. Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Archives of Internal Medicine 2003 Aug;163(15):1793-8.
26. Iravani A, Richard GA. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrobial Agents and Chemotherapy 1986 Jan;29(1):107-11.
27. Gold JA, Hegarty CP, Deitch MW, Walker BR. Double-blind clinical trials of oral cyclacillin and ampicillin. Antimicrobial Agents and Chemotherapy 1979 Jan;15(1):55-8.
28. Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. American Journal of Hospital Pharmacy 1979 Jun;36(6):754-7.
29. Fernández-Bañares F, Esteve M, Espinós JC, Rosinach M, Forné M, Salas A, Viver JM. Drug consumption and the risk of microscopic colitis. The American Journal of Gastroenterology 2007 Feb;102(2):324-30.
30. Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. The American Journal of Gastroenterology 2015;110(5):749-59.
31. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. The Canadian Journal of Psychiatry 2002 Mar;47(2):174-80.
32. Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. International Clinical Psychopharmacology 1996 Sep;11(3):157-64.
33. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs & Aging 1998 Sep;13(3):245-53.
34. Ahluwalia NK, Thompson DG, Barlow J, Heggie L. Beta adrenergic modulation of human upper intestinal propulsive forces. Gut 1994 Oct;35(10):1356-9.
35. Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, Carbonnel F. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2016 Oct;65(10):1664-9.
36. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe sprue-like enteropathy associated with olmesartan. Mayo Clinic Proceedings 2012 Aug;87(8):732-8.
37. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced enteropathy. Digestive Diseases 2015;33(2):215-20.
38. Ebrahim VS, Martin J, Murthy S, Odstrcil E, Huang H, Polter D. Olmesartan-associated enteropathy. Proceedings (Baylor University Medical Center) 2017 Jul;30(3):348-50.
39. Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human Pathology 2016 Apr;50:127-34.
40. Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, Hutfless SM. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterology Report 2019 Jun;7(3):162-7.
41. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011 Mar;57(3):413-20.
42. Herman M, Rubio-Tapia A, Marietta E, Wu TT, Murray J. Severe enteropathy in a patient on valsartan. The American Journal of Gastroenterology 2013 Oct;108:302.
43. Cammarota G, Ianiro G, Bibbò S, Gasbarrini A. Letter: telmisartan-associated enteropathy – is there any class effect? Authors’ reply. Alimentary Pharmacology & Therapeutics 2014 Sep;40(5):570.
44. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobichon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib F, Méresse B, Cerf-Bensussan N, Malamut G, Carbonnel F. Olmesartan-associated enteropathy: results of a national survey. Alimentary Pharmacology & Therapeutics 2014 Nov;40(9):1103-9.
45. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy – is there any class effect? Alimentary Pharmacology & Therapeutics 2014 Sep;40(5):569-70.
46. Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiology in Review 2011 Nov-Dec;19(6):300-4.
47. Guédon C, Bruna T, Ducrotté P, Lerebours E, Denis P, Colin R. Diarrhée sévère sous Ticlid associée à des troubles de la motricité du grêle [Severe diarrhea caused by Ticlid associated with disorders of small intestine motility]. Gastroentérologie Clinique et Biologique 1989;13(11):934-7.
48. Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Postgraduate Medicine Journal 2014 Jul;90(1065):411-9.
49. Berrebi D, Sautet A, Flejou JF, Dauge MC, Peuchmaur M, Potet F. Ticlopidine induced colitis: a histopathological study including apoptosis. Journal of Clinical Pathology 1998 Apr;51(4):280-3.
50. Abdominal Key. Drug-induced diarrhea. Available from: https://abdominalkey.com/drug-induced-diarrhea Accessed 2021 Aug 23.
51. Pentland B, Pennington CR. Acute diarrhoea in the elderly. Age & Ageing 1980 May;9(2):90-2.
52. Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998 Mar;21(3):409-15.
53. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44 (Suppl 3):47-53.
54. Abraham B, Sellin JH. Drug-induced diarrhea. Current Gastroenterology Reports 2007 Oct;9(5):365-72.
55. Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. American Journal of Health-System Pharmacy 1996 Oct;53(19):2277-90.
56. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. The American Journal of Medicine 1995 May;98(5):443-51.
57. Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptis SA, Naditch L. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Research and Clinical Practice 2001 Mar;51(3):205-13.
58. Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, Akanle O, Ajjan R, Kola B, Stadler M, Fraser W, Christ-Crain M, Grossman AB, Pitzalis C, Korbonits M. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. The Lancet. Diabetes & Endocrinology 2020 Apr;8(4):278-91.
59. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. The American Journal of Medicine 1997 Dec;103(6):491-7.
60. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005 Oct;143(8):559-69.
61. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. The Lancet. Oncology 2013 Jul;14(8):697-710.
62. Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clinical Colorectal Cancer 2015;14(2):72-80.
63. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009 Apr;360(14):1408-17.
64. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet. Oncology 2014 Sep;15(10):1065-75.
65. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Journal of Clinical Oncology 2006 May;24(15):2283-9.
66. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment 2014 Oct;25(5):401-8.
67. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology 2013;24:1813-21.
68. Freeman HJ. Colitis associated with biological agents. World Journal of Gastroenterology 2012 Apr;18(16):1871-4.
69. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncology 2019 Jul;5(7):1008-19.
70. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018 Mar;360:k793.
71. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 2005 Jul;353(2):123-32.
72. McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Frontiers in Pharmacology 2016 Nov;7:414.
73. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology 2004 Jul;22(14):2918-26.
74. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. The New England Journal of Medicine 2002 Jan;346(2):85-91.
75. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O’Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet. Oncology 2013 Jul;14(8):749-59.
76. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology 2012 Sep;13(9):897-905.
77. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, Verbois L, Ghosh D, Wilson W, Duan J, Sarker H, Miksinski SP, Skarupa L, Ibrahim A, Justice R, Murgo A, Pazdur R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clinical Cancer Research 2012 Jul;18(14):3722-30.
78. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 Jan;30(2):134-41.
79. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011 Mar;29(8):1067-74.
80. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011 Mar;29(8):1059-66.
81. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. The New England Journal of Medicine 2014 Oct;371(17):1609-18.
82. Walko CM, Lindley C. Capecitabine: a review. Clinical Therapeutics 2005 Jan;27(1):23-44.
83. Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. European Journal of Cancer 2017 May;77:40-7.
84. Binder HJ. The gastroenterologist’s osmotic gap: fact or fiction? Gastroenterology 1992 Aug;103(2):702-4.
85. Fine KD, Ogunji F, Florio R, Porter J, Ana CS. Investigation and diagnosis of diarrhea caused by sodium phosphate. Digestive Diseases and Sciences 1998 Dec;43(12):2708-14.
86. Abraham BP, Sellin JH. Drug-induced, factitious, & idiopathic diarrhoea. Best Practice & Research. Clinical Gastroenterology 2012 Oct;26(5):633-48.
87. Hyams JS. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterology 1983;84(1):30-3.
88. McRorie J, Zorich N, Riccardi K, Bishop L, Filloon T, Wason S, Giannella R. Effects of olestra and sorbitol consumption on objective measures of diarrhea: impact of stool viscosity on common gastrointestinal symptoms. Regulatory Toxicology and Pharmacology 2000 Feb;31(1):59-67.
89. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. Journal of Clinical Investigation 1989 Oct;84(4):1056-62.
90. Erckenbrecht J, Kienle U, Zöllner L, Wienbeck M. Effects of high dose antacids on bowel motility. Digestion 1982;25(4):244-7.
91. Bircher J, Haemmerli UP, Scollo-Lavizzari G, Hoffmann K. Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. The American Journal of Medicine 1971 Aug;51(2):148-59.
92. Cummings JH, Sladen GE, James OF, Sarner M, Misiewicz JJ. Laxative-induced diarrhoea: a continuing clinical problem. British Medical Journal 1974 Mar;1(5907):537-41.
93. Solomon R, Cherny NI. Constipation and diarrhea in patients with cancer. Cancer Journal (Sudbury, Mass.) 2006 Sep-Oct;12(5):355-64.
94. Owen RT. Lubiprostone – a novel treatment for irritable bowel syndrome with constipation. Drugs of Today (Barcelona, Spain: 1998) 2008 Sep;44(9):645-52.
95. Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB Jr, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Digestive Diseases and Sciences 2011 Sep;56(9):2639-45.
96. Castell D, Silvers D, Littlejohn T, Orr W, Napolitano J, Oleka N, Jokubaitis L. Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group. Alimentary Pharmacology & Therapeutics 1999 Jun;13(6):787-94.
97. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. The American Journal of Gastroenterology 1995 Mar;90(3):423-30.
98. Castell DO, Sigmund C Jr, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. The American Journal of Gastroenterology 1998 Apr;93(4):547-52.
99. Müller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. The American Journal of Gastroenterology 2006 Nov;101(11):2558-69.
100. Lucendo AJ. Drug exposure and the risk of microscopic colitis: a critical update. Drugs in R&D 2017 Mar;17(1):79-89.
101. Pasricha PJ. Treatment of disorders of bowel motility and water flux; antiemetics: agents used in biliary and pancreatic disease. In: Goodman & Gilman’s the pharmacological basis of therapeutics. Brunton LL, Lazo J, Parker K, editors. 11th ed. New York: McGraw Hill; 2006: 983-1008.
102. Gracon SI, Knapp MJ, Berghoff WG, Pierce M, DeJong R, Lobbestael SJ, Symons J, Dombey SL, Luscombe FA, Kraemer D. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Disease & Associated Disorders 1998 Jun;12(2):93-101.
103. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998 Jan;50(1):136-45.
104. Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013 Nov;185(16):1393-401.
105. Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, Ivory JD, Khan PA, Yazdi F, Ghassemi M, Blondal E, Ho JM, Ng CH, Hemmelgarn B, Majumdar SR, Perrier L, Straus SE. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network meta-analysis. Journal of the American Geriatrics Society 2018 Jan;66(1):170-8.
106. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992 May;33(5):683-6.
107. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. The Cochrane Database of Systematic Reviews 2014 Feb 10;(2):CD005117.
108. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs & Aging 1995 Nov;7(5):372-93.
109. Altman RD, Strand V, Hochberg MC, Gibofsky A, Markenson JA, Hopkins WE, Cryer B, Kivitz A, Nezzer J, Imasogie O, Young CL. Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: a 1-year, open-label, phase III safety study. Postgraduate Medicine 2015 Jun;127(5):517-28.
110. Walker C, Essex MN, Li C, Park PW. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. The Journal of International Medical Research 2016 Jun;44(3):483-95.
111. Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Current Medical Research and Opinion 2014 Sep;30(9):1883-93.
112. Roddy E, Clarkson K, Blagojevic-Bucknall M, Mehta R, Oppong R, Avery A, Hay EM, Heneghan C, Hartshorne L, Hooper J, Hughes G, Jowett S, Lewis M, Little P, McCartney K, Mahtani KR, Nunan D, Santer M, Williams S, Mallen CD. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the Rheumatic Diseases 2020 Feb;79(2):276-84.
113. Thörn M, Sjöberg D, Ekbom A, Holmström T, Larsson M, Nielsen AL, Holmquist L, Thelander U, Wanders A, Rönnblom A. Microscopic colitis in Uppsala health region, a population-based prospective study 2005-2009. Scandinavian Journal of Gastroenterology 2013 Jul;48(7):825-30.
114. Shimura S, Hamamoto N, Yoshino N, Kushiyama Y, Fujishiro H, Komazawa Y, Furuta K, Ishihara S, Adachi K, Kinoshita Y. Diarrhea caused by proton pump inhibitor administration: comparisons among lansoprazole, rabeprazole, and omeprazole. Current Therapeutic Research, Clinical and Experimental 2012 Jun;73(3):112-20.
115. Nelson MR, Moyle GJ, Gazzard BG. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus. Clinical Infectious Diseases 1993 Feb;16(Suppl 1):S59-62.
116. Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, Leleu G, Calvez V; AI454-176 JAGUAR Study Team. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. The Journal of Infectious Diseases 2005 Mar;191(6):840-7.
117. Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clinical Infectious Diseases 1993 Feb;16(Suppl 1):S63-8.
118. Poles MA, Fuerst M, McGowan I, Elliott J, Rezaei A, Mark D, Taing P, Anton PA. HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. The American Journal of Gastroenterology 2001 Jun;96(6):1831-7.
119. Kessler HA, Johnson J, Follansbee S, Sension MG, Mildvan D, Sepulveda GE, Bellos NC, Hetherington SV. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clinical Infectious Diseases 2002 Feb;34(4):535-42.
120. Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (London, England) 2004 Jul;18(11):1529-37.
121. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndroms 2004 Jan;35(1):22-32.
122. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U; STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology, Dialysis, Transplantation 2008 Nov;23(11):3654-61.
123. Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. Journal of Clinical Oncology 1996 Oct;14(10):2682-7.
124. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001 Feb;33(2):433-8.
125. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. The New England Journal of Medicine 2000 Dec;343(23):1673-80.
126. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. The New England Journal of Medicine 2000 Dec;343(23):1666-72.
127. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 1995 Aug;123(4):241-9.
128. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clinical and Experimental Rheumatology 1993 Mar-Apr;11(Suppl 8):117-9.
129. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Annals of Surgery 1992 Oct;216(4):513-8.
130. Bunnapradist S, Ambühl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clinical Transplantation 2008 Nov-Dec;22(6):815-21.
131. Goyal A, Salahuddin M, Govil Y. A unique case of mycophenolate induced colitis after 10 years of use. Case Reports in Gastrointestinal Medicine 2016;2016:3058407.
132. Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, Bhamidimarri KR. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Annals of Gastroenterology 2015 Jul-Sep;28(3):366-73.
133. Curtin BF, Rachakonda VP, Von Rosenvinge EC. Unusually late-onset mycophenolate mofetil-related colitis. American Journal of Health System Pharmacy 2014 Nov;71(21):1858-61.
134. Chande N, Driman DK, Reynolds RP. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scandinavian Journal of Gastroenterology 2005 Mar;40(3):343-7.
135. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. The Lancet 1998 Jul;352(9123):167-72.
136. Gray TK, Bieberdorf FA, Fordtran JS. Thyrocalcitonin and the jejunal absorption of calcium, water, and electrolytes in normal subjects. The Journal of Clinical Investigation 1973 Dec;52(12):3084-8.
137. Ehrenfeld M, Levy M, Sharon P, Rachmilewitz D, Eliakim M. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Digestive Diseases and Sciences 1982 Aug;27(8):723-7.
138. Stemmermann GN, Hayashi T. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Human Pathology 1971 Jun;2(2):321-32.
139. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. The New England Journal of Medicine 2019 Dec;381(26):2497-505.
140. Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders 2015 Aug;15:96.
141. Campbell DES, Berglindh T. Pharmacology of olsalazine. Scandinavian Journal of Gastroenterology. Supplement 1988;23(48):7-12.
142. Sandberg-Gertzén H, Järnerot G, Bukhave K, Lauritsen K, Rask-Madsen J. Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 in subjects with a permanent ileostomy. Gut 1986 Nov;27(11):1306-11.
143. Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflammatory Bowel Disease 2005 Mar;11(3):253-7.
144. Scheurlen C, Allgayer H, Kruis W, Erdmann E, Sauerbruch T. Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? The Clinical Investigator 1993 Apr;71(4):286-9.
145. Raimundo AH, Patil DH, Frost PG, Silk DB. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects [published correction appears in Gut 1991 May;32(5):552]. Gut 1991;32(3):270-4.
146. Sellin JH. The pathophysiology of diarrhea. Clinical Transplantation 2001;15(Suppl 4):2-10.
147. Hill DB, Henderson LM, McClain CJ. Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. JPEN. Journal of Parenteral and Enteral Nutrition 1991 May-Jun;15(3):332-6.
148. Hamilton I, O’Connor HJ, Wood NC, Bradbury I, Axon AT. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Gut 1986 Jan;27(1):106-10.
149. Papadopolous C, Kalantzis N, Rekoumis G, Kanaghinis T. A comparative trial of 400 mg cimetidine twice daily and 1000 mg daily in the short-term treatment of duodenal ulceration. Current Medical Research and Opinion 1985;9(8):511-5.
150. Wallin BA, McCafferty JP, Fox MJ, Cooper DR, Goldschmidt MS. Incidence and management of diarrhea during longterm auranofin therapy. The Journal of Rheumatology 1988 Dec;15(12):1755-8.
151. Champion GD, Cairns DR, Bieri D, Adena MA, Browne CD, Cohen ML, Day RO, Edmonds JP, Graham GG, de Jager J. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. The Journal of Rheumatology 1988 Jan;15(1):28-34.
152. D’Arcy PF, Griffin JP. Iatrogenic diseases. 3rd ed. New York: Oxford University Press; 1986. 573 p.
153. Jackson CW, Haboubi NY, Whorwell PJ, Schofield PF. Gold induced enterocolitis. Gut 1986 Apr;27(4):452-6.
154. Forston WC, Tedesco FJ. Drug induced colitis: a review. The American Journal of Gastroenterology1984 Nov;79(11):878-83.
155. Mauricio AC, Slawik M, Heitzmann D, von Hahn T, Warth R, Bleich M, Greger R. Deoxycholic acid (DOC) affects the transport properties of distal colon. Pflügers Archiv 2000 Mar;439(5):532-40.
156. Venkatasubramanian J, Selvaraj N, Carlos M, Skaluba S, Rasenick MM, Rao MC. Differences in Ca(2+) signaling underlie age-specific effects of secretagogues on colonic Cl(-) transport. American Journal of Physiology. Cell Physiology 2001 Mar;280(3):C646-58.
157. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid – adverse effects and drug interactions. Alimentary Pharmacology & Therapeutics 2003 Nov;18(10):963-72.
158. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 1984 Feb;27(2):95-131.
159. Sackmann M, Pauletzki J, Aydemir U, Holl J, Sauerbruch T, Hasford J, Paumgartner G. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991 Dec;14(6):1136-41.
160. Wasan SM, Sellin JH, Vassilopoulou-Sellin R. The gastrointestinal tract and liver in thyrotoxicosis. In: Werner & Ingbar’s the thyroid: a fundamental and clinical text. Braverman LE, Utiger RD, editors. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 589-94.
161. Baker JT, Harvey RF. Bowel habits in thyrotoxicosis and hyperthyroidism. British Medical Journal 1971 Feb;1(5744):322-3.
162. Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhoea, and lymphocytic colitis. Gut 1995 Nov;37(5):708-11.
163. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. Journal of Clinical Oncology 2001 Sep;19(18):3801-7.
164. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. The New England Journal of Medicine 2000 Sep;343(13):905-14.
165. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. The New England Journal of Medicine 2002 Jan;346(5):334-9.
166. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L, Englund G, Nord CE, Svenungsson B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. The Journal of Antimicrobial Chemotherapy 2001 Jan;47(1):43-50.
167. Montoya M, Detorres O. Antimicrobial selection and its impact on the incidence of Clostridium difficile-associated diarrhea. Journal of Pharmacy Practice 2013 Oct;26(5):483-7.
168. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clinical Infectious Diseases 1998 Oct;27(4):702-10.
169. Piacenti FJ, Leuthner KD. Antimicrobial stewardship and Clostridium difficile-associated diarrhea. Journal of Pharmacy Practice 2013 Oct;26(5):506-13.
170. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Therapeutics Advances in Medical Oncology 2010 Jan;2(1):51-63.
171. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. Journal of Pain and Symptom Management 2000 Feb;19(2):118-29.
172. Парфенов А.И. Диарея. Русский медицинский журнал 1998;7:6.
173. Шмидт Р., Тевс Г. Физиология человека. В 3-х т. 3-е изд. М.: Мир; 2005.
174. Chang EB, Leung PS. Intestinal water and electrolyte transport. In: The gastrointestinal system. Brunton LL, Chabner BA, Knollman BC, editors. Netherlands: Springer; 2014: 107-34.
175. Sharkey KA, Wallace JL. Treatment of disorders of bowel motility and water flux; anti-emetics; agents used in biliary and pancreatic disease. In: Goodman & Gilman’s the pharmacological basis of therapeutics. Shanahan JF, Naglieri C, editors.12th ed. New York: McGraw-Hill; 2011. 1328 p.
176. Phillips S, Donaldson L, Geisler K, Pera A, Kochar R. Stool composition in factitial diarrhea: a 6-year experience with stool analysis. Annals of Internal Medicine 1995 Jul;123(2):97-100.
177. Field M. Intestinal ion transport and the pathophysiology of diarrhea. The Journal of Clinical Investigation 2003 Apr;111(7):931-43.
178. Pilotto A, Franceschi M, Vitale D, Zaninelli A, Di Mario F, Seripa D, Rengo F; FIRI (Fondazione Italiana Ricerca sull’Invecchiamento); SOFIA Project Investigators. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. The American Journal of Gastroenterology 2008 Nov;103(11):2816-23.
179. Schiller LR. Definitions, pathophysiology, and evaluation of chronic diarrhoea. Best Practice & Research. Clinical Gastroenterology 2012 Oct;26(5):551-62.
180. Fine KD, Ogunji F. A new method of quantitative fecal fat microscopy and its correlation with chemically measured fecal fat output. American Journal of Clinical Pathology 2000 Apr;113(4):528-34.
181. Simko V. Fecal fat microscopy. Acceptable predictive value in screening for steatorrhea. The American Journal of Gastroenterology 1981 Mar;75(3):204-8.
182. Amann ST, Josephson SA, Toskes PP. Acid steatocrit: a simple, rapid gravimetric method to determine steatorrhea. The American Journal of Gastroenterology 1997 Dec;92(12):2280-4.
183. Peled Y, Doron O, Laufer H, Bujanover Y, Gilat T. D-xylose absorption test. Urine or blood? Digestive Diseases and Sciences 1991 Feb;36(2):188-92.
184. Elli L, Branchi F, Tomba C, Villalta D, Norsa L, Ferretti F, Roncoroni L, Bardella MT. Diagnosis of gluten related disorders: celiac disease, wheat allergy and non-celiac gluten sensitivity. World Journal of Gastroenterology 2015 Jun;21(23):7110-9.
185. NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C, Camargo CA Jr, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. The Journal of Allergy and Clinical Immunology 2010 Dec;126(6 Suppl):S1-58.
186. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA; American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. The Americal Journal of Gastroenterology 2013 May;108(5):656-76; quiz 677.
187. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. The Americal Journal of Gastroenterology 2013 Apr;108(4):478-98.
188. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control & Hospital Epidemiology 2010 May;31(5):431-55.
189. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015 Jan;313(4):398-408.
190. Сычев Д.А., Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М.В., Аляутдинова И.А., Голобородова И.В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека 2020;27(6):113-26.
191. Sherman AL, Ojeda-Correal G, Mena J. Use of glucosamine and chondroitin in persons with osteoarthritis. PM&R 2012 May;4(5 Suppl):S110-6.
192. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982;3(3):157-68.
193. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Safety 2009;32(8):637-47.

References

1. Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, Ramakrishna BS, Goh KL, Thomson A, Khan AG, Krabshuis J, LeMair A; WGO. Acute diarrhea in adults and children: a global perspective. Journal of Clinical Gastroenterology 2013 Jan;47(1):12-20.
2. Barr W, Smith A. Acute diarrhea. American Family Physician 2014 Feb;89(3):180-9.
3. DuPont HL. Acute infectious diarrhea in immunocompetent adults. The New England Journal of Medicine 2014 Apr;370(16):1532-40.
4. Philip NA, Ahmed N, Pitchumoni CS. Spectrum of drug-induced chronic diarrhea. Journal of Clinical Gastroenterology 2017 Feb;51(2):111-7.
5. Drug induced diseases: prevention, detection, and management. Tisdale JE, Miller DA, editors. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 p.
6. Shiber S, Yahav D, Avni T, Leibovici L, Paul M. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. The Journal of Antimicrobial Chemotherapy 2015 Jan;70(1):41-7.
7. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs 2007;67(7):1027-52.
8. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. The American Journal of Medicine 1985 Jun;78(6A):73-8.
9. Teppler H. Safety and tolerability of ertapenem. The Journal of Antimicrobial Chemotherapy 2004 Jun;53(Suppl 2):ii75-81.
10. Norrby SR, Gildon КМ. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scandinavian Journal of Infectious Diseases 1999;31(1):3-10.
11. Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ. Ertapenem: review of a new carbapenem. Expert Review of Anti-Infective Therapy 2005 Feb;3(1):23-39.
12. Zhanel GG, Simor AE, Vercaigne L, Mandell L; Canadian Carbapenem Discussion Group. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. The Canadian Journal of Infectious Diseases 1998 Jul;9(4):215-28.
13. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Alimentary Pharmacology & Therapeutics 1998 Dec;12(12):1217-23.
14. Gooch WM 3rd, Philips A, Rhoades R, Rosenberg R, Schaten R, Starobin S. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. The Pediatric Infectious Disease Journal 1997 Feb;16(2 Suppl):S21-4.
15. Harrison CJ, Chartrand SA, Pichichero ME. Microbiologic and clinical aspects of a trial of once daily cefixime compared with twice daily cefaclor for treatment of acute otitis media in infants and children. The Pediatric Infectious Disease Journal 1993 Jan;12(1):62-9.
16. Meyers BR. Comparative toxicities of third-generation cephalosporins. The American Journal of Medicine 1985 Aug;79(2A):96-103.
17. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Safety1993 Aug;9(2):132-42.
18. Nahata MC, Miller MA. Diarrhoea associated with ceftriaxone and its implications in paediatric patients. Journal of Clinical Pharmacy & Therapeutics 1989 Aug;14(4):305-7.
19. Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. The American Journal of Medicine 1988 Sep;85(3A):6-13.
20. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Safety 2000 Jan;22(1):53-72.
21. Swartzberg JE, Maresca RM, Remington JS. Clinical study of gastrointestinal complications associated with clindamycin therapy. The Journal of Infectious Diseases 1977 Mar;135 (Suppl):S99-103.
22. Arguedas A, Emparanza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ, Espinoza G. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. The Pediatric Infectious Disease Journal 2005 Feb;24(2):153-61.
23. Weber FH Jr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. The American Journal of Gastroenterology 1993 Apr;88(4):485-90.
24. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. The Journal of Pediatric Pharmacology and Therapeutics 2015;20(2):90-104.
25. Bucher HC, Tschudi P, Young J, Périat P, Welge-Lüussen A, Züst H, Schindler C; BASINUS (Basel Sinusitis Study) Invetigators. Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Archives of Internal Medicine 2003 Aug;163(15):1793-8.
26. Iravani A, Richard GA. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrobial Agents and Chemotherapy 1986 Jan;29(1):107-11.
27. Gold JA, Hegarty CP, Deitch MW, Walker BR. Double-blind clinical trials of oral cyclacillin and ampicillin. Antimicrobial Agents and Chemotherapy 1979 Jan;15(1):55-8.
28. Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. American Journal of Hospital Pharmacy 1979 Jun;36(6):754-7.
29. Fernández-Bañares F, Esteve M, Espinós JC, Rosinach M, Forné M, Salas A, Viver JM. Drug consumption and the risk of microscopic colitis. The American Journal of Gastroenterology 2007 Feb;102(2):324-30.
30. Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. The American Journal of Gastroenterology 2015;110(5):749-59.
31. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. The Canadian Journal of Psychiatry 2002 Mar;47(2):174-80.
32. Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. International Clinical Psychopharmacology 1996 Sep;11(3):157-64.
33. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs & Aging 1998 Sep;13(3):245-53.
34. Ahluwalia NK, Thompson DG, Barlow J, Heggie L. Beta adrenergic modulation of human upper intestinal propulsive forces. Gut 1994 Oct;35(10):1356-9.
35. Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, Carbonnel F. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2016 Oct;65(10):1664-9.
36. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe sprue-like enteropathy associated with olmesartan. Mayo Clinic Proceedings 2012 Aug;87(8):732-8.
37. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced enteropathy. Digestive Diseases 2015;33(2):215-20.
38. Ebrahim VS, Martin J, Murthy S, Odstrcil E, Huang H, Polter D. Olmesartan-associated enteropathy. Proceedings (Baylor University Medical Center) 2017 Jul;30(3):348-50.
39. Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human Pathology 2016 Apr;50:127-34.
40. Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, Hutfless SM. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterology Report 2019 Jun;7(3):162-7.
41. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011 Mar;57(3):413-20.
42. Herman M, Rubio-Tapia A, Marietta E, Wu TT, Murray J. Severe enteropathy in a patient on valsartan. The American Journal of Gastroenterology 2013 Oct;108:302.
43. Cammarota G, Ianiro G, Bibbò S, Gasbarrini A. Letter: telmisartan-associated enteropathy – is there any class effect? Authors’ reply. Alimentary Pharmacology & Therapeutics 2014 Sep;40(5):570.
44. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobichon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib F, Méresse B, Cerf-Bensussan N, Malamut G, Carbonnel F. Olmesartan-associated enteropathy: results of a national survey. Alimentary Pharmacology & Therapeutics 2014 Nov;40(9):1103-9.
45. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy – is there any class effect? Alimentary Pharmacology & Therapeutics 2014 Sep;40(5):569-70.
46. Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiology in Review 2011 Nov-Dec;19(6):300-4.
47. Guédon C, Bruna T, Ducrotté P, Lerebours E, Denis P, Colin R. Diarrhée sévère sous Ticlid associée à des troubles de la motricité du grêle [Severe diarrhea caused by Ticlid associated with disorders of small intestine motility]. Gastroentérologie Clinique et Biologique 1989;13(11):934-7.
48. Philpott HL, Nandurkar S, Lubel J, Gibson PR. Drug-induced gastrointestinal disorders. Postgraduate Medicine Journal 2014 Jul;90(1065):411-9.
49. Berrebi D, Sautet A, Flejou JF, Dauge MC, Peuchmaur M, Potet F. Ticlopidine induced colitis: a histopathological study including apoptosis. Journal of Clinical Pathology 1998 Apr;51(4):280-3.
50. Abdominal Key. Drug-induced diarrhea. Available from: https://abdominalkey.com/drug-induced-diarrhea Accessed 2021 Aug 23.
51. Pentland B, Pennington CR. Acute diarrhoea in the elderly. Age & Ageing 1980 May;9(2):90-2.
52. Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998 Mar;21(3):409-15.
53. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44 (Suppl 3):47-53.
54. Abraham B, Sellin JH. Drug-induced diarrhea. Current Gastroenterology Reports 2007 Oct;9(5):365-72.
55. Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. American Journal of Health-System Pharmacy 1996 Oct;53(19):2277-90.
56. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. The American Journal of Medicine 1995 May;98(5):443-51.
57. Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptis SA, Naditch L. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Research and Clinical Practice 2001 Mar;51(3):205-13.
58. Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, Akanle O, Ajjan R, Kola B, Stadler M, Fraser W, Christ-Crain M, Grossman AB, Pitzalis C, Korbonits M. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. The Lancet. Diabetes & Endocrinology 2020 Apr;8(4):278-91.
59. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. The American Journal of Medicine 1997 Dec;103(6):491-7.
60. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005 Oct;143(8):559-69.
61. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. The Lancet. Oncology 2013 Jul;14(8):697-710.
62. Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clinical Colorectal Cancer 2015;14(2):72-80.
63. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009 Apr;360(14):1408-17.
64. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet. Oncology 2014 Sep;15(10):1065-75.
65. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Journal of Clinical Oncology 2006 May;24(15):2283-9.
66. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment 2014 Oct;25(5):401-8.
67. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology 2013;24:1813-21.
68. Freeman HJ. Colitis associated with biological agents. World Journal of Gastroenterology 2012 Apr;18(16):1871-4.
69. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncology 2019 Jul;5(7):1008-19.
70. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018 Mar;360:k793.
71. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 2005 Jul;353(2):123-32.
72. McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Frontiers in Pharmacology 2016 Nov;7:414.
73. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. Journal of Clinical Oncology 2004 Jul;22(14):2918-26.
74. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. The New England Journal of Medicine 2002 Jan;346(2):85-91.
75. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O’Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet. Oncology 2013 Jul;14(8):749-59.
76. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology 2012 Sep;13(9):897-905.
77. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, Verbois L, Ghosh D, Wilson W, Duan J, Sarker H, Miksinski SP, Skarupa L, Ibrahim A, Justice R, Murgo A, Pazdur R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clinical Cancer Research 2012 Jul;18(14):3722-30.
78. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 Jan;30(2):134-41.
79. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011 Mar;29(8):1067-74.
80. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011 Mar;29(8):1059-66.

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]